ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1712

Head and Neck Involvement of IgA Vasculitis: A Case-Control Study

Michel Villatoro-Villar1, David Wetter 1, Cynthia Crowson 2, Kenneth Warrington 1 and Matthew Koster 1, 1Mayo Clinic Rochester, Rochester, MN, 2Mayo Clinic Rochester, Rochester

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Henoch-Schönlein purpura and skin, iga, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Behçet’s Disease & Other Vasculitides

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: IgA vasculitis (IgAV) is an immune-complex mediated, small-vessel vasculitis which predominantly involves the skin on the lower extremities. Head and neck involvement is rarely reported. The purpose of this study was to describe the presentation and outcome of a series of patients with head and/or neck involvement in comparison to patients with cutaneous findings isolated to the lower extremities.

Methods: Patients with biopsy-proven IgAV from January 1, 1997 through December 31, 2016 were retrospectively identified through direct medical chart review. IgAV was diagnosed in accordance with the American College of Rheumatology (ACR) and the European League Against Rheumatism/ Paediatric Rheumatology European Society/Paediatric Rheumatology International Trials Organisation (EULAR/PRINTO/PRES) criteria. Among this cohort, patients with documented clinical, photographic, or histologic descriptions of vasculitic skin lesions affecting the head or neck were compiled. Each patient with head/neck (H/N) involvement of IgAV (case) was matched to two age- and sex-matched control patients with IgAV for which the cutaneous features were isolated to the waistline or distal. Baseline characteristics, laboratory parameters, treatments and outcome were collected by a physician abstractor.

Results: Thirteen patients with H/N-IgAV involvement were identified. Baseline characteristics of the cases and controls are demonstrated in Table 1. H/N involvement included facial (cheeks, forehead) [n=6], perioral/oral/lip [n=6], auricular [n=2], nasal [n=2], and neck [n=1]. All patients in both groups had evidence of purpuric skin lesions. Patients with H/N-IgAV involvement more frequently had evidence of skin ulcerations (23% vs. 0%; p=0.01) [Figure 1]. Overall baseline renal involvement and microscopic hematuria were less commonly observed in patients with H/N-IgAV. Among H/N-IgAV cases, at last follow-up all had resolution of H/N lesions but 3 of 13 had persistent skin lesions on the lower extremities despite ongoing treatment. Long-term outcome between cases and controls did not identify any significant differences in the development of end-stage renal disease, time to resolution of hematuria or proteinuria, time to complete IgAV response, or time to first IgAV relapse.

Conclusion: This study reports the largest series of patients with head/neck involvement of IgA, a rarely reported entity. In this cohort, patients with H/N-IgAV had less frequent renal involvement compared to IgAV patients with lower extremity only skin lesions. Clinicians should be aware of atypical locations of IgAV involvement. Additional research is needed to further understand this clinical subset.

Figure 1: A- H/N involvement in IgAV -perioral, nasal, cheeks and neck-. B- Severe PP in lower extremities with bullous, ulcerations and skin necrosis.


Table 1_1

Table 1: Baseline characteristics of patients with head and neck involvement of IgA-vasculitis compared to those with lower extremity only skin lesions


Disclosure: M. Villatoro-Villar, None; D. Wetter, None; C. Crowson, Crescendo Bioscience, 5, Crescendo BioScience Inc., 5, Crescendo Bioscience Inc., 5, Crescendo Biosciences inc., 5, Pfizer, 2; K. Warrington, Eli Lilly, 2, GlaxoSmithKline, 2, roche, 2, 8, Roche, 2, 5, 8, Sanofi, 5, sanofi, 5; M. Koster, None.

To cite this abstract in AMA style:

Villatoro-Villar M, Wetter D, Crowson C, Warrington K, Koster M. Head and Neck Involvement of IgA Vasculitis: A Case-Control Study [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/head-and-neck-involvement-of-iga-vasculitis-a-case-control-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/head-and-neck-involvement-of-iga-vasculitis-a-case-control-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology